CFO John P. Hamill resigns; John Tattory appointed interim CFO effective Jan 27, 2023

WINDTREE THERAPEUTICS INC /DE/

John P. Hamill resigns as CFO effective Jan 27, 2023 for personal reasons; no disagreement with company.
John Tattory appointed Interim CFO effective Jan 27, 2023; will serve as principal financial and accounting officer.
Tattory previously served as Windtree CFO from 2014 to 2020; will consult via LifeSci Associates at hourly rate.
Company to commence search for a permanent CFO.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

John P. Hamill

Senior Vice President, Chief Financial Officer and Corporate Secretary

WINT · WINDTREE THERAPEUTICS INC /DE/

Effective: 2023-01-27
Successor: John Tattory
Filed: January 19, 2023, 6:59 PM ET

On January 17, 2023, John P. Hamill, the Senior Vice President, Chief Financial Officer and Corporate Secretary of Windtree Therapeutics, Inc. (the “Company”) notified the Company of his decision to resign effective as of January 27, 2023 (the “Effective Date”).

Appointed (interim)

John Tattory

Interim Chief Financial Officer

WINT · WINDTREE THERAPEUTICS INC /DE/

Effective: 2023-01-27
Filed: January 19, 2023, 6:59 PM ET

On January 18, 2023, the board of directors of the Company appointed John Tattory as Interim Chief Financial Officer, effective as of the Effective Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John P. Hamill resigned as Senior Vice President, Chief Financial Officer and Corporate Secretary at WINDTREE THERAPEUTICS INC /DE/.

Action: resigned
Role: Senior Vice President, Chief Financial Officer and Corporate Secretary

Exact text from the filing

On January 17, 2023, John P. Hamill, the Senior Vice President, Chief Financial Officer and Corporate Secretary of Windtree Therapeutics, Inc. (the “Company”) notified the Company of his decision to resign effective as of January 27, 2023 (the “Effective Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

John Tattory was appointed as Interim Chief Financial Officer at WINDTREE THERAPEUTICS INC /DE/.

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

On January 18, 2023, the board of directors of the Company appointed John Tattory as Interim Chief Financial Officer, effective as of the Effective Date.

View on SEC.gov

WINDTREE THERAPEUTICS INC /DE/ filing history →

Source: SEC EDGAR

accession 0001437749-23-001281

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.